Target intelligence / Profile preview

Large neutral amino acids transporter small subunit 3 (LAT3)

Target
LAT3
Molecular classification
Transporter, Solute carrier family protein, L-type amino acid transporter, Membrane protein
01

Overview

SLC43A1, encoding Large neutral amino acids transporter small subunit 3 (LAT3), is a sodium-independent membrane transporter responsible for the facilitated diffusion of large neutral amino acids—particularly leucine, isoleucine, valine, methionine, and phenylalanine—into cells[1][2][3][5]. LAT3 plays a crucial role in supplying essential amino acids required for mTORC1 pathway activation, which controls cell growth and protein synthesis[1]. Its expression is upregulated in various cancers, notably prostate cancer, where it is regulated by androgen receptor signaling and nutrient stress responses[1]. Elevated LAT3 promotes cancer cell proliferation, and experimental inhibition of LAT3 can suppress tumor growth by restricting amino acid availability[1]. LAT3 is found in multiple tissues, including pancreas, skin, muscle, liver, kidney podocytes, and prostate[1].

Other names
LAT3SLC43A1Large neutral amino acids transporter small subunit 3L-type amino acid transporter 3Prostate cancer overexpressed gene 1 proteinPOV1PB39R00504
02

Mechanism of action

Inhibitors block amino acid uptake, depriving cancer cells of essential nutrients for mTORC1-mediated protein synthesis, thereby suppressing cell growth and proliferation

03

Biological functions

Neutral (large) amino acid transport (facilitated diffusion of leucine, isoleucine, valine, methionine, phenylalanine)Regulation of protein synthesis and cell growth via the mTORC1 pathwayNutrient supply to rapidly proliferating cells
04

Disease associations

Cancer (notably prostate cancer and other malignancies)SeminomaEncephalomalacia (rare, less established)
05

Safety considerations

Systemic inhibition of LAT3 may also reduce amino acid uptake in non-tumor tissues, potentially impacting metabolic homeostasis, growth, and organ functionOff-target effects due to broad amino acid transporter inhibition
06

Interacting drugs

No specific drugs directly targeting LAT3 are clinically established, but LAT family inhibitors and experimental compounds have been developed (e.g., inhibitors for LAT1/LAT3 such as BCH, acivicin, and 3-iodo-L-tyrosine)
07

Biomarkers

LAT3 expression in prostate tissue (especially in cancer), used as a biomarker for cancer aggressiveness and potential progressionLAT3 mRNA/protein levels in tumor tissue

Beyond the preview

Go deeper on Large neutral amino acids transporter small subunit 3 (LAT3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Large neutral amino acids transporter small subunit 3 (LAT3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call